Effects of androgen excess and body mass index on endothelial function in women with polycystic ovary syndrome

被引:5
|
作者
Berbrier, Danielle E.
Leone, Cheryl A. [1 ,2 ]
Adler, Tessa E. [1 ,2 ]
Bender, Jeffrey R. [3 ,4 ]
Taylor, Hugh S. [5 ]
Stachenfeld, Nina S. [1 ,2 ,5 ]
Usselman, Charlotte W. [1 ,2 ,5 ,6 ]
机构
[1] McGill Univ, Dept Kinesiol & Phys Educ, Cardiovasc Hlth & Auton Regulat Lab, Montreal, PQ, Canada
[2] Yale Sch Med, John B Pierce Lab, New Haven, CT 06520 USA
[3] Yale Sch Med, Dept Internal Med Cardiovasc Med & Immunobiol, New Haven, CT USA
[4] Yale Cardiovasc Res Ctr, Yale Sch Med, New Haven, CT USA
[5] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
[6] McGill Univ, McGill Res Ctr Phys Act & Hlth, Montreal, PQ, Canada
关键词
androgen excess; endothelial dysfunction; ethinyl estradiol; fl ow -mediated dilation; polycystic ovary syndrome; FLOW-MEDIATED DILATION; CARDIOVASCULAR-DISEASE RISK; TYPE-2; DIABETES-MELLITUS; INSULIN-RESISTANCE; BRACHIAL-ARTERY; YOUNG-WOMEN; NONINVASIVE ASSESSMENT; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; BLOOD-PRESSURE;
D O I
10.1152/japplphysiol.00583.2022
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Polycystic ovary syndrome (PCOS) is associated with endothelial dysfunction; whether this is attributable to comorbid hyperandrogen-ism and/or obesity remains to be established. Therefore, we 1) compared endothelial function between lean and overweight/obese (OW/OB) women with and without androgen excess (AE)-PCOS and 2) examined androgens as potential modulators of endothelial function in these women. The flow-mediated dilation (FMD) test was applied in 14 women with AE-PCOS (lean: n = 7; OW/OB: n = 7) and 14 controls (CTRL; lean: n = 7, OW/OB: n = 7) at baseline (BSL) and following 7 days of ethinyl estradiol supplementation (EE; 30 lg/day) to assess the effect of a vasodilatory therapeutic on endothelial function; at each time point we assessed peak increases in diameter during reactive hyperemia (%FMD), shear rate, and low flow-mediated constriction (%LFMC). BSL %FMD was attenuated in lean AE-PCOS versus both lean CTRL (5.2 +/- 1.5 vs. 10.3 +/- 2.6%, P < 0.01) and OW/OB AE-PCOS (5.2 +/- 1.5 vs. 6.6 +/- 0.9%, P = 0.048). A negative correlation between BSL %FMD and free testosterone was observed in lean AE-PCOS only (R2 = 0.68, P = 0.02). EE increased %FMD in both OW/OB groups (CTRL: 7.6 +/- 0.6 vs. 10.4 +/- 2.5%, AE-PCOS: 6.6 +/- 0.9 vs. 9.6 +/- 1.7%, P < 0.01), had no impact on %FMD in lean AE-PCOS (5.17 +/- 1.5 vs. 5.17 +/- 1.1%, P = 0.99), and reduced %FMD in lean CTRL (10.3 +/- 2.6 vs. 7.6 +/- 1.2%, P = 0.03). Collectively, these data indicate that lean women with AE-PCOS exhibit more severe endothelial dysfunction than their OW/OB coun-terparts. Furthermore, endothelial dysfunction appears to be mediated by circulating androgens in lean but not in OW/OB AE-PCOS, suggesting a difference in the endothelial pathophysiology of AE-PCOS between these phenotypes. NEW & NOTEWORTHY We present evidence for marked endothelial dysfunction in lean women with androgen excess polycys-tic ovary syndrome (AE-PCOS) that is 1) associated with free testosterone levels, 2) impaired relative to overweight/obese women with AE-PCOS, and 3) unchanged following short-term ethinyl estradiol supplementation. These data indicate an important direct effect of androgens on the vascular system in women with AE-PCOS. Our data also suggest that the relationship between andro-gens and vascular health differs between phenotypes of AE-PCOS.
引用
收藏
页码:868 / 878
页数:11
相关论文
共 50 条
  • [21] Polycystic Ovary Syndrome and the Neuroendocrine Consequences of Androgen Excess
    Silva, Mauro S. B.
    Campbell, Rebecca E.
    [J]. COMPREHENSIVE PHYSIOLOGY, 2022, 12 (02) : 3347 - 3369
  • [22] Serum androgen levels and muscle mass in women with polycystic ovary syndrome
    Douchi, T
    Yamamoto, S
    Oki, T
    Maruta, K
    Kuwahata, R
    Nagata, Y
    [J]. OBSTETRICS AND GYNECOLOGY, 1999, 94 (03): : 337 - 340
  • [23] SEXUAL FUNCTION AND ASSOCIATIONS WITH ANDROGEN LEVELS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
    Pastoor, Hester
    Both, Stephanie
    Laan, Ellen
    Laven, Joop
    [J]. JOURNAL OF SEXUAL MEDICINE, 2023, 20
  • [24] Prevalence of insulin resistance among american women with polycystic ovary syndrome (PCOS) as a function of body mass index (BMI).
    Dahan, M. H.
    Abbasi, F.
    Reaven, G.
    [J]. FERTILITY AND STERILITY, 2007, 88 : S78 - S79
  • [25] Sexual function in women with androgen excess disorders: classic forms of congenital adrenal hyperplasia and polycystic ovary syndrome
    Kepczynska-Nyk, A.
    Kurylowicz, A.
    Nowak, A.
    Bednarczuk, T.
    Ambroziak, U.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (03) : 505 - 513
  • [26] Sexual function in women with androgen excess disorders: classic forms of congenital adrenal hyperplasia and polycystic ovary syndrome
    A. Kępczyńska-Nyk
    A. Kuryłowicz
    A. Nowak
    T. Bednarczuk
    U. Ambroziak
    [J]. Journal of Endocrinological Investigation, 2021, 44 : 505 - 513
  • [27] Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society
    Moran, Lisa J.
    Pasquali, Renato
    Teede, Helena J.
    Hoeger, Kathleen M.
    Norman, Robert J.
    [J]. FERTILITY AND STERILITY, 2009, 92 (06) : 1966 - 1982
  • [28] Comparison of Central Fat Accumulation Indices with Body Mass Index in Women with Polycystic Ovary Syndrome
    Singh, Neha
    Hooja, Nupur
    [J]. JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA, 2023, 73 (SUPPL 1): : 156 - 160
  • [29] A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome
    Xita, N
    Georgiou, L
    Tsatsoulis, A
    Kourtis, A
    Kukuvitis, A
    Panidis, D
    [J]. FERTILITY AND STERILITY, 2004, 82 (05) : 1466 - 1467
  • [30] Increased epicardial fat thickness is related with body mass index in women with polycystic ovary syndrome
    Soydinc, E.
    Soydinc, S.
    Ariturk, Z.
    Tekbas, E.
    Cakici, M.
    Islamoglu, Y.
    Ercan, S.
    Sari, I.
    Davutoglu, V.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (15) : 2111 - 2113